We use our versatile Ambifect® Fc-fusion protein platform to invent and develop a diverse pipeline of therapeutic candidates for indications in Animal Health.
We partner with Animal Health companies that can take our novel therapeutics to market and maintain close involvement with our partners in the development and manufacturing process.
Animal Health
Long Acting Fc-Fusion proteins
once-a-week dosing
AKS-321d is a once-a-week insulin therapy for dogs, intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-321d.
once-a-week dosing
AKS-425c is a once-a-week insulin therapy for cats, intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-425c.
Therapeutic vaccines
Human Health
Akston has developed the human versions of some of its Animal Health candidates. Once these Human Health candidates have completed early in vivo testing, Akston makes them available for licensing to companies to advance their development to the IND-enabling and clinical study stages.
Human health candidates
Akston developed a room temperature stable, low-cost CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. We are seeking Emergency Use Authorization (EAU) in India for this vaccine, and for its ‘universal’ booster vaccine capability. In 2023, Akston licensed this patent to Vakston for continued development.
Akston has developed AKS-107, a designer Fc-insulin fusion protein, to interrupt the process leading to insulin autoimmunity. Akston partnered with the Helmsley Charitable Trust and the National Institutes of Health (NIH) in the early development stages. In 2023, Akston licensed this patent to Diamune, Inc. for continued development.
once-a-week dosing
Akston has developed AKS-440, a novel human insulin candidate based on the Ambifect™ Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. It is currently in pre-clinical development.
Akston has developed AKS-130, an insulin-Fc fusion protein designed to lower blood glucose levels in order to target the tumor cell insulin receptors. It is currently in pre-clinical development.
